- 866-356-4281 from the United States and Canada or
- 617-597-5395 (International)
- 888-286-8010 from the United States and Canada or
- 617-801-6888 (International)
If the messy, confused clinical data disclosed Saturday by XBiotech are any indication, an approval in Europe for its colon cancer drug is far from a sure thing.
These under-$10 biotech stocks are within range of triggering breakout trades.